Learning Objectives:

1) Understand the potential of ctDNA assessment as a strong prognostic biomarker to inform recurrence in patients with peritoneal metastasis undergoing curative resection.
2)  Understand the importance of ctDNA assessment as a stratification factor in designing clinical trials to inform further therapy.
3)  Understand the potential role of NGS-based ctDNA assessment in discovering actionable targets for peritoneal disease.

Session date: 
02/14/2022 - 9:00am to 10:00am CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Ankit Dhiman